<HashMap><database>biostudies-arrayexpress</database><scores/><additional><omics_type>Unknown</omics_type><omics_type>Transcriptomics</omics_type><omics_type>Genomics</omics_type><omics_type>Proteomics</omics_type><submitter>Patrick Nylund</submitter><study_type>methylation profiling by array</study_type><organism>Homo sapiens</organism><species>Homo sapiens</species><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/E-MTAB-14582</full_dataset_link><description>Epigenetic therapies of the multiple myeloma cell line INA-6 under different treatment conditions</description><repository>biostudies-arrayexpress</repository><sample_protocol>Growth Protocol - The MM cell line INA-6 was cultured in RPMI-1640 AQmediaTM media (Sigma) supplemented with 10% heat-inactivated FBS (Sigma), 1% GlutaMAXTM-I and antibiotics (penicillin 100U/ml and streptomycin 50 mg/mL; Sigma) and Interleukin-6 (IL-6) at 37°C in a humidified 5% CO2 in-air atmosphere incubator. Exponentially growing cells were seeded at 100.000 cells/mL and incubated overnight before addition of reagents. Every 72h, cells were split in equal numbers and re-plated.</sample_protocol><sample_protocol>Scaning - Illumina Infinium MethylationEPIC array</sample_protocol><sample_protocol>Sample Treatment - Exponentially growing INA-6 cells were seeded at 100.000 cells/mL and incubated overnight before addition of vehicle DMSO, 0.5µM UNC1999, 50nM 5-azacytidine or the combination of 0.5µM UNC1999 and 50nM 5-azacytidine for 9 days.</sample_protocol><sample_protocol>Sample Collection - The INA-6 MM cell line was treated with vehicle DMSO, 0.5µM UNC1999, 50nM 5-azacytidine or the combination of both 0.5µM UNC1999 and 50nM 5-azacytidine for the total of 9 days, and global DNA methylation was assessed after bisulfite conversion.</sample_protocol><sample_protocol>Nucleic Acid Extraction - Bisulfite conversion was performed using the EZ DNA MethylationTM Kit (Zymo Research #D5004) with 250 ng of DNA per sample. The bisulfite-converted DNA was eluted in 15μl according to the manufacturer´s protocol.</sample_protocol><sample_protocol>Labeling - The ddCTP and ddGTP are labeled with biotin while ddATP and ddUTP are labeled DNP.</sample_protocol><sample_protocol>Hybridization - Hybridization is followed by single-base extension with hapten-labeled dideoxynucleotides.</sample_protocol><figure_sub>MIAME Score</figure_sub><figure_sub>Raw Data</figure_sub><figure_sub>Organization</figure_sub><figure_sub>Assays and Data</figure_sub><figure_sub>MAGE-TAB Files</figure_sub><figure_sub>Array Designs</figure_sub><pubmed_authors>Antonia Kalushkova</pubmed_authors><pubmed_authors>Patrick Nylund</pubmed_authors></additional><is_claimable>false</is_claimable><name>EPIC INA6</name><description>Epigenetic therapies of the multiple myeloma cell line INA-6 under different treatment conditions</description><dates><release>2025-12-30T00:00:00Z</release><modification>2025-12-30T02:02:06.681Z</modification><creation>2024-11-03T23:03:01.126Z</creation></dates><accession>E-MTAB-14582</accession><cross_references><EFO>EFO_0002944</EFO><EFO>EFO_0003814</EFO><EFO>EFO_0003813</EFO><EFO>EFO_0003789</EFO><EFO>EFO_0002759</EFO><EFO>EFO_0005518</EFO><EFO>EFO_0003815</EFO><EFO>EFO_0003969</EFO></cross_references></HashMap>